Drug intelligence / Profile preview

rPSGL-Ig

Development stage
Phase 2
Lead developer
Thios Pharmaceuticals
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a recombinant fusion protein composed of the human P-selectin glycoprotein ligand 1 (PSGL-1) fused to the Fc region of human immunoglobulin G1. It acts as a selectin antagonist, blocking leukocyte adhesion by binding to selectins and thereby inhibiting neutrophil entry into inflamed or ischemic tissues. This mechanism reduces inflammatory responses and tissue injury, particularly in settings such as transplantation ischemia-reperfusion injury and myocardial infarction. The drug has been investigated for use in conditions including myocardial infarction, delayed graft function after organ transplantation, glomerulonephritis, anemia, red blood cell disorders, and kidney transplant surgery[1][2][4][6][8].

Brand names
Torapsel
Other names
Recombinant P-selectin glycoprotein ligand-immunoglobulin IgRecombinant soluble PSGL-1 Fc chimera
02

Targets

SELE (E-selectin)SELL (L-selectin)SELP (P-selectin)

Beyond the preview

Go deeper on rPSGL-Ig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rPSGL-Ig.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call